A phase 2 study is investigating another survivin-targeting vaccine, DPX-Survivac, in conjunction with cyclophosphamide and pembrolizumab in recurrent ovarian cancer (NCT03029403). The gene discussed is BIRC5; the disease is ovarian carcinoma.